Dyno Therapeutics and Trisk Bio have announced a strategic manufacturing partnership via the former’s expanded Frontiers Program.
Trisk Bio becomes the first Frontiers manufacturing partner in Dyno’s expanded Frontiers Program, forming an integrated developer-manufacturer network intended to cut down risk for gene therapy developers and speed up progress toward genetic agency.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Announced in May 2025, the Dyno Frontiers Program helps gene therapy innovators prove the therapeutic potential of their genetic medicines by giving them access to Dyno’s AI-designed adeno-associated virus (AAV) capsids and non-human primate study expertise.
The expanded programme now adds a manufacturing marketplace for all participants, aiming to remove technical obstacles that have historically slowed development and restricted patient benefit.
Trisk Bio contributes expertise in intensified, fully scaleable, high‑purity AAV manufacturing.
As Dyno’s inaugural Frontiers manufacturing partner, Trisk has robust, optimised production processes tailored to Dyno’s proprietary gene‑delivery capsids, giving therapeutic developers clearer predictability around yields, costs, timelines and overall manufacturing results.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDyno Therapeutics CEO and cofounder Eric Kelsic stated: “We’re excited to build the first initiative that integrates developers, technology providers and AAV capsid manufacturers, creating an end-to-end partnership network that promotes faster development of novel gene therapies at lower cost and with less execution risk.
“Expanding the Dyno Frontiers Program to now include manufacturing partners reflects our conviction that an ecosystem with healthy competition and collaboration is essential to broadening the patient impact of gene therapies and to enabling genetic agency, so that all patients can take action at the genetic level to live a healthier life.”
The expanded programme provides therapeutic developers with immediate access to manufacturers having experience with Dyno’s capsids, thereby reducing uncertainty, speeding readiness for nonhuman primate studies, and creating a clear route to clinical-scale production.
Trisk Bio CEO Gaurav Venkataraman stated: “We’ve worked with Dyno for over a year, developing fully scaleable manufacturing processes for several novel Dyno capsids, including purification exclusively by chromatography. We’re impressed by Dyno’s commitment to ensuring that their partners have a proven path to clinical and commercial scale.”
Via a robust ecosystem, the two companies intend to lower the costs of gene therapy development and make it more feasible to develop new treatments for rare and ultra-rare diseases that have long been underexplored.
